Our top pick for
Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.
Agile Therapeutics, Inc is a drug manufacturers—specialty & generic business based in the US. Agile Therapeutics shares (AGRX) are listed on the NASDAQ and all prices are listed in US Dollars. Agile Therapeutics employs 15 staff and has a market cap (total outstanding shares value) of USD$264.1 million.
Since the stock market crash in March caused by coronavirus, Agile Therapeutics's share price has had significant negative movement.
Its last market close was USD$2.93, which is 5.33% down on its pre-crash value of USD$3.095 and 117.04% up on the lowest point reached during the March crash when the shares fell as low as USD$1.35.
If you had bought USD$1,000 worth of Agile Therapeutics shares at the start of February 2020, those shares would have been worth USD$424.74 at the bottom of the March crash, and if you held on to them, then as of the last market close they'd be worth USD$787.64.
|Latest market close||USD$2.93|
|52-week range||USD$0.35 - USD$4.7652|
|50-day moving average||USD$3.194|
|200-day moving average||USD$2.7826|
|Wall St. target price||USD$8.5|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||USD$-0.42|
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2020-11-24)||3.90%|
|1 month (2020-10-30)||7.72%|
|3 months (2020-09-01)||-0.68%|
|6 months (2020-06-01)||0.34%|
|1 year (2019-11-29)||39.52%|
|2 years (2018-11-30)||237.83%|
|3 years (2017-12-01)||-41.28%|
|5 years (2015-12-01)||-67.41%|
|Gross profit TTM||USD$0|
|Return on assets TTM||-27.6%|
|Return on equity TTM||-56.16%|
|Market capitalisation||USD$264.1 million|
TTM: trailing 12 months
There are currently 3.2 million Agile Therapeutics shares held short by investors – that's known as Agile Therapeutics's "short interest". This figure is 24% down from 4.3 million last month.
There are a few different ways that this level of interest in shorting Agile Therapeutics shares can be evaluated.
Agile Therapeutics's "short interest ratio" (SIR) is the quantity of Agile Therapeutics shares currently shorted divided by the average quantity of Agile Therapeutics shares traded daily (recently around 1.7 million). Agile Therapeutics's SIR currently stands at 1.94. In other words for every 100,000 Agile Therapeutics shares traded daily on the market, roughly 1940 shares are currently held short.
However Agile Therapeutics's short interest can also be evaluated against the total number of Agile Therapeutics shares, or, against the total number of tradable Agile Therapeutics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Agile Therapeutics's short interest could be expressed as 0.04% of the outstanding shares (for every 100,000 Agile Therapeutics shares in existence, roughly 40 shares are currently held short) or 0.0458% of the tradable shares (for every 100,000 tradable Agile Therapeutics shares, roughly 46 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Agile Therapeutics.
Find out more about how you can short Agile Therapeutics stock.
We're not expecting Agile Therapeutics to pay a dividend over the next 12 months.
Over the last 12 months, Agile Therapeutics's shares have ranged in value from as little as $0.35 up to $4.7652. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Agile Therapeutics's is 1.4247. This would suggest that Agile Therapeutics's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Agile Therapeutics, Inc., a women's healthcare company, focuses on the research, development, and commercialization of prescription contraceptive products for women. Its lead product candidate is Twirla, also known as AG200-15, a once-weekly prescription contraceptive patch. The company is also developing a pipeline of Twirla line extensions and other transdermal contraceptive products, including AG200-ER, a regimen that allows a woman to extend the length of her cycle; AG200-SP, which is a regimen designed to provide shorter and lighter periods; AG200-ER (SmP), a regimen to allow a woman to extend the length of her cycle, as well as experience shorter and lighter periods; and AG890, a progestin-only contraceptive patch intended for use by women who are unable or unwilling to take estrogen. Agile Therapeutics, Inc. was founded in 1997 and is headquartered in Princeton, New Jersey.
Everything we know about the Qilian International Holding Group IPO, plus information on how to buy in.
Everything we know about the AbCellera Biologics IPO, plus information on how to buy in.
Steps to owning and managing CALM, with 24-hour and historical pricing before you buy.
Steps to owning and managing CRR, with 24-hour and historical pricing before you buy.
Steps to owning and managing BG, with 24-hour and historical pricing before you buy.
Steps to owning and managing BCLI, with 24-hour and historical pricing before you buy.
Steps to owning and managing BLBD, with 24-hour and historical pricing before you buy.
Steps to owning and managing BDTX, with 24-hour and historical pricing before you buy.
Steps to owning and managing RILYO, with 24-hour and historical pricing before you buy.
Steps to owning and managing ASPN, with 24-hour and historical pricing before you buy.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.